EUVIMEDEUVIMED entdecken
FallberichtLeserbriefOpen Access

Rapid symptomatic improvement in two patients with ganglioglioma after restarting BRAF inhibitor therapy

Evan Cantor iD, Rachel Berkovich, Pournima Navalkele, Nicole M Brossier

Pediatric Blood & Cancer · 2023

DOI: 10.1002/pbc.30296 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Pediatric Blood & Cancer, 2023. Verfasst von Evan Cantor und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Connecticut Children's Medical Center, Hartford, Connecticut, USA. Hauptthemen laut MEDLINE: Ganglioglioma, Brain Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To the Editor: Gangliogliomas (GG) are composed ofmixed neuronal and glial components and are commonly associated with neurologic symptoms that vary by tumor location. Biologically targeted agents such as the BRAF inhibitors dabrafenib and vemurafenib are now used to treat progressive low-grade gliomas (LGG), including GG,1,2 but the effect of these agents on the neurologic symptoms that may accompany LGGs is poorly understood.3 Here, we describe clinical and radiographic response from single-therapy BRAF inhibition in two patients with

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GangliogliomaBrain NeoplasmsHumansProto-Oncogene Proteins B-rafMutation

Substanzen

Proto-Oncogene Proteins B-rafBRAF protein, human

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Connecticut Children's Medical Center, Hartford, Connecticut, USA.
  • Department of Pediatrics, UCONN School of Medicine, Farmington, Connecticut, USA.
  • Departments of Radiology, Children's Mercy Hospital, Kansas City, Missouri, USA.
  • Division of Pediatric Oncology, Children's Hospital of Orange County, Orange, California, USA.
  • Departments of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA.

ORCID-Profile: Evan Cantor

Förderung

  • NICHD NIH HHS

Zitieren

APA

Cantor, E., Berkovich, R., Navalkele, P., & Brossier, N. M. (2023). Rapid symptomatic improvement in two patients with ganglioglioma after restarting BRAF inhibitor therapy. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30296

Vancouver

Cantor E, Berkovich R, Navalkele P, Brossier NM. Rapid symptomatic improvement in two patients with ganglioglioma after restarting BRAF inhibitor therapy. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30296

BibTeX
@article{Cantor2023,
  author = {Cantor, Evan and Berkovich, Rachel and Navalkele, Pournima and Brossier, Nicole M},
  title = {Rapid symptomatic improvement in two patients with ganglioglioma after restarting BRAF inhibitor therapy},
  journal = {Pediatric Blood & Cancer},
  year = {2023},
  doi = {10.1002/pbc.30296}
}
Kostenlos starten →